CoChat

Decreasing antibiotic resistance trends nationally in gram-negative bacteria across United States Veterans Affairs medical centers, 2011-2020.

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Gram-negative resistance is a well-acknowledged public health threat. Surveillance data can be used to monitor resistance trends and identify strategies to mitigate their threat. The objective of this study was to assess antibiotic resistance trends in Gram-negative bacteria. METHODS: The first cultures of Pseudomonas aeruginosa, Citrobacter, Escherichia coli, Enterobacter, Klebsiella, Morganella morganii, Proteus mirabilis, and Serratia marcescens per hospitalized patient per month collected from 125 Veterans Affairs Medical Centers (VAMCs) between 2011 to 2020 were included. Time trends of resistance phenotypes (carbapenem, fluoroquinolone, extended-spectrum cephalosporin, multi-drug, and difficult-to-treat) were analyzed with Joinpoint regression to estimate average annual percent changes (AAPC) with 95% confidence intervals and p values. A 2020 antibiogram of reported antibiotic percent susceptibilities was also created to evaluate resistance rates at the beginning of the COVID-19 pandemic. RESULTS: Among 40 antimicrobial resistance phenotype trends assessed in 494,593 Gram-negative isolates, there were no noted increases; significant decreases were observed in 87.5% (n = 35), including in all P. aeruginosa, Citrobacter, Klebsiella, M. morganii, and S. marcescens phenotypes (p < 0.05). The largest decreases were seen in carbapenem-resistant phenotypes of P. mirabilis, Klebsiella, and M. morganii (AAPCs: - 22.9%, - 20.7%, and - 20.6%, respectively). In 2020, percent susceptibility was over 80% for all organisms tested against aminoglycosides, cefepime, ertapenem, meropenem, ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem-vaborbactam. CONCLUSION: We observed significant decreases in antibiotic resistance for P. aeruginosa and Enterobacterales over the past decade. According to the 2020 antibiogram, in vitro antimicrobial activity was observed for most treatment options. These results may be related to the robust infection control and antimicrobial stewardship programs instituted nationally among VAMCs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40121-023-00827-9

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Distribution of organisms (n = 494,593) by culture site. Included organisms are ordered on the x axis in the figure by the most prevalent, and each organism was stratified by percentage into the following collection sites on the y axis: urine, respiratory, skin and tissue, blood, and other. The “other” category included, but was not limited to, the following collection sites: bone and joint, catheter, cerebrospinal fluid, intra-abdominal
Fig. 1 Distribution of organisms (n = 494,593) by culture site. Included organisms are ordered on the x axis in the figure by the most prevalent, and each organism was stratified by percentage into the following collection sites on the y axis: urine, respiratory, skin and tissue, blood, and other. The “other” category included, but was not limited to, the following collection sites: bone and joint, catheter, cerebrospinal fluid, intra-abdominalCC BY-NC · PubMed Central
Fig. 2 Trends in antimicrobial resistance phenotypes for Pseudomonas aeruginosa, Veterans Affairs Medical Centers, 2011–2020. Time trends indicated by average annual percent changes (AAPCs), 95% confidence intervals (CIs), and p values for the following antimicrobial resistance phenotypes: multi-drug resistance (MDR), difficult-to-treat resistance (DTR), extended-spectrum cephalosporin resistance (ESCR), carbapenem resistance (CR), and fluoroquinolone resistance (FR). Percent resistance on the y axis, maximum scale value of 40%
Fig. 2 Trends in antimicrobial resistance phenotypes for Pseudomonas aeruginosa, Veterans Affairs Medical Centers, 2011–2020. Time trends indicated by average annual percent changes (AAPCs), 95% confidence intervals (CIs), and p values for the following antimicrobial resistance phenotypes: multi-drug resistance (MDR), difficult-to-treat resistance (DTR), extended-spectrum cephalosporin resistance (ESCR), carbapenem resistance (CR), and fluoroquinolone resistance (FR). Percent resistance on the y axis, maximum scale value of 40%CC BY-NC · PubMed Central
Fig. 3 Trends in antimicrobial resistance phenotypes for a Citrobacter species, b Enterobacter species, c Klebsiella species, d Serratia marcescens, Veterans Affairs Medical Centers, 2011–2020. Time trends indicated by average annual percent changes (AAPCs), 95% confidence intervals (CIs), and p values for the following antimicrobial resistance phenotypes: multi-drug resistance (MDR), difficult-to-treat resistance (DTR), extended-spectrum cephalosporin resistance (ESCR), carbapenem resistance (CR), and fluoroquinolone resistance (FR). Percent resistance on the y axis, maximum scale value of 40% for all figures
Fig. 3 Trends in antimicrobial resistance phenotypes for a Citrobacter species, b Enterobacter species, c Klebsiella species, d Serratia marcescens, Veterans Affairs Medical Centers, 2011–2020. Time trends indicated by average annual percent changes (AAPCs), 95% confidence intervals (CIs), and p values for the following antimicrobial resistance phenotypes: multi-drug resistance (MDR), difficult-to-treat resistance (DTR), extended-spectrum cephalosporin resistance (ESCR), carbapenem resistance (CR), and fluoroquinolone resistance (FR). Percent resistance on the y axis, maximum scale value of 40% for all figuresCC BY-NC · PubMed Central
Fig. 4 Trends in antimicrobial resistance phenotypes for a Escherichia coli, b Morganella morganii, c Proteus mirabilis, Veterans Affairs Medical Centers, 2011–2020. Time trends indicated by average annual percent changes (AAPCs), 95% confidence intervals (CIs), and p values for the following antimicrobial resistance phenotypes: multi-drug resistance (MDR), difficult-to-treat resistance (DTR), extended-spectrum cephalosporin resistance (ESCR), carbapenem resistance (CR), and fluoroquinolone resistance (FR). Percent resistance on the y axis, maximum scale value of 55% for all figures
Fig. 4 Trends in antimicrobial resistance phenotypes for a Escherichia coli, b Morganella morganii, c Proteus mirabilis, Veterans Affairs Medical Centers, 2011–2020. Time trends indicated by average annual percent changes (AAPCs), 95% confidence intervals (CIs), and p values for the following antimicrobial resistance phenotypes: multi-drug resistance (MDR), difficult-to-treat resistance (DTR), extended-spectrum cephalosporin resistance (ESCR), carbapenem resistance (CR), and fluoroquinolone resistance (FR). Percent resistance on the y axis, maximum scale value of 55% for all figuresCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 5

  1. WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Geneva: World Health Organization; 2017.
  2. WHO. WHO policy guidance on integrated antimicrobial stewardship activities. Geneva: World Health Organization; 2021.
  3. CLSI. Performance standards for antimicrobial susceptibility testing: twentieth informational supplement M100–S20. Wayne: Clinical and Laboratory Standards Institute; 2020.
  4. FDA. Drug safety communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections; warns about disabling side effects that can occur together. Press release. Silver Spring: US Food and Drug Administration; 2016.
  5. CDC. 2022 special report: COVID-19 US impact on antimicrobial resistance. Atlanta: US Centers for Disease Control and Prevention; 2022.

Cited by

See all 17

Metadata

Authors
Liao, J. X., Appaneal, H. J., Menon, A., Lopes, V., LaPlante, K. L., & Caffrey, A. R.
Affiliations
  • University of Rhode Island (US)
  • Brown University (US)
  • Providence VA Medical Center (US)
Corresponding author
  • LaPlante, Kerry L.
  • Caffrey, Aisling R.
Venue
Infectious Diseases and Therapy
Published
2023-06-16
Volume
12
Issue
7
Pages
1835-1848
ISSN
  • 2193-6382 (ISSN-L)
  • 2193-8229
OpenAlex
W4380872152
Cited by
16
References
28
Citations by year
2026: 1 · 2025: 6 · 2024: 6 · 2023: 3
FWCI
1.37
Type
journal article
Language
en
Open access
Licence
Locations
  • Infectious Diseases and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
U.S. Department of Veterans Affairs
Topics
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
  • Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
  • Health Sciences › Medicine › Urology › Urinary Tract Infections Management
Keywords
antibiotic resistance trends, Gram-negative bacteria, veterans, Pseudomonas aeruginosa, Enterobacterales, carbapenem resistance, fluoroquinolone resistance, extended-spectrum cephalosporins, multidrug resistance, Klebsiella, Morganella morganii, Proteus mirabilis, Serratia marcescens, Citrobacter, Escherichia coli, antimicrobial susceptibility, infection control, COVID-19 pandemic, antimicrobial stewardship

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Decreasing antibiotic resistance trends nationally in gram-negative bacteria across United States Veterans Affairs medical centers, 2011-2020. https://app.cochat.ai/papers/10.1007/s40121-023-00827-9
The paper
Liao, J. X., Appaneal, H. J., Menon, A., Lopes, V., LaPlante, K. L., & Caffrey, A. R. (2023). Decreasing antibiotic resistance trends nationally in gram-negative bacteria across United States Veterans Affairs medical centers, 2011-2020. Infectious Diseases and Therapy. https://doi.org/10.1007/s40121-023-00827-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.